Adverum Biotechnologies – Talk Bio

Actionable Insights Powered by AI

Eli Lilly to Acquire Adverum Biotechnologies in Gene Therapy Deal; Captain T Cell Secures €20M Funding

3 weeks ago talkbio0Tagged Acquisition, Adverum Biotechnologies, biotech, Captain T Cell, contingent value rights, CVR, eli lilly, financing characteristics, gene therapy, Investments, Ixo-vec, Ophthalmology specialty

Eli Lilly; Adverum Biotechnologies; Acquisition; Gene therapy; Ixo-vec; Contingent Value Rights (CVR); Ophthalmology; Captain T Cell; Financing; Biotech investment

Lilly Expands Gene Therapy Presence with Acquisition of Adverum Biotechnologies

2 months ago talkbio0Tagged Acquisition, Adverum Biotechnologies, contingent value, eli lilly, gene therapy, ixovec, Ophthalmology specialty, Wet Age-Related Macular Degeneration

Eli Lilly; Adverum Biotechnologies; gene therapy; ophthalmology; wet age-related macular degeneration; ixovec; acquisition; contingent value rights